Inventiva S.A [IVA] vs Nanobiotix [NANO] Detailed Stock Comparison
Inventiva S.A
Euronext
Loading...
Nanobiotix
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Inventiva S.A wins in 5 metrics, Nanobiotix wins in 10 metrics, with 1 ties. Nanobiotix appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Inventiva S.A | Nanobiotix | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -0.94 | -4.13 | Nanobiotix |
| Price-to-Book Ratio | -1.05 | N/A | N/A |
| Debt-to-Equity Ratio | -1.70 | -0.77 | Inventiva S.A |
| PEG Ratio | -2.08 | -5.63 | Nanobiotix |
| EV/EBITDA | -3.82 | -4.16 | Nanobiotix |
| Profit Margin (TTM) | 0.00% | 0.00% | Tie |
| Operating Margin (TTM) | -384.43% | 271.42% | Nanobiotix |
| EBITDA Margin (TTM) | N/A | 271.42% | N/A |
| Return on Equity | 172.73% | 103.70% | Inventiva S.A |
| Return on Assets (TTM) | -63.60% | -52.89% | Nanobiotix |
| Free Cash Flow (TTM) | $-86.26M | $-20.40M | Nanobiotix |
| 1-Year Return | 34.26% | 45.31% | Nanobiotix |
| Price-to-Sales Ratio (TTM) | 28.71 | -39.36 | Nanobiotix |
| Enterprise Value | $357.93M | $281.33M | Inventiva S.A |
| EV/Revenue Ratio | 25.40 | -39.13 | Nanobiotix |
| Revenue per Share (TTM) | $0 | $0 | Inventiva S.A |
| Earnings per Share (Diluted) | $-3.08 | $-1.44 | Nanobiotix |
| Beta (Stock Volatility) | 0.62 | 1.50 | Inventiva S.A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Inventiva S.A vs Nanobiotix Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Inventiva S.A | 1.05% | 3.94% | 5.45% | -7.35% | 27.75% | 37.44% |
| Nanobiotix | 5.31% | 7.99% | 35.11% | 110.96% | 64.94% | 106.84% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Inventiva S.A | 34.26% | -45.28% | -70.88% | -65.02% | -65.02% | -65.02% |
| Nanobiotix | 45.31% | 56.02% | -8.90% | -64.31% | 2.42% | 2.42% |
Performance & Financial Health Analysis: Inventiva S.A vs Nanobiotix
| Metric | IVA | NANO |
|---|---|---|
| Market Information | ||
| Market Cap | €404.66M | €283.01M |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 108,036 | 301,738 |
| 90 Day Avg. Volume | 62,815 | 177,091 |
| Last Close | €2.90 | €6.35 |
| 52 Week Range | €1.43 - €3.30 | €2.62 - €6.45 |
| % from 52W High | -12.12% | -1.55% |
| All-Time High | €16.30 (Jan 18, 2021) | €33.12 (Feb 10, 2014) |
| % from All-Time High | -82.21% | -80.83% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.30% | N/A |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | -3.84% | 2.71% |
| Return on Equity (TTM) | 1.73% | 1.04% |
| Debt to Equity (MRQ) | -1.70 | -0.77 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €-1.12 | €-1.39 |
| Cash per Share (MRQ) | €1.01 | €1.05 |
| Operating Cash Flow (TTM) | €-85,928,000 | €-19,551,000 |
| Levered Free Cash Flow (TTM) | €-56,252,248 | €-33,155,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Inventiva S.A vs Nanobiotix
| Metric | IVA | NANO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -0.94 | -4.13 |
| Forward P/E | -2.08 | -5.63 |
| PEG Ratio | -2.08 | -5.63 |
| Price to Sales (TTM) | 28.71 | -39.36 |
| Price to Book (MRQ) | -1.05 | N/A |
| Market Capitalization | ||
| Market Capitalization | €404.66M | €283.01M |
| Enterprise Value | €357.93M | €281.33M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 25.40 | -39.13 |
| Enterprise to EBITDA | -3.82 | -4.16 |
| Risk & Other Metrics | ||
| Beta | 0.62 | 1.50 |
| Book Value per Share (MRQ) | €-1.12 | €-1.39 |
Financial Statements Comparison: Inventiva S.A vs Nanobiotix
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IVA | NANO |
|---|---|---|
| Revenue/Sales | €65,000 | N/A |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | €11.91M | N/A |
| Operating Income (EBIT) | €-13.67M | N/A |
| EBITDA | €-13.43M | N/A |
| Pre-Tax Income | €-14.27M | N/A |
| Income Tax | €21,000 | N/A |
| Net Income (Profit) | €-14.30M | N/A |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IVA | NANO |
|---|---|---|
| Cash & Equivalents | €96.56M | €49.74M |
| Total Current Assets | €111.51M | €61.47M |
| Total Current Liabilities | €120.73M | €58.94M |
| Long-Term Debt | €48.46M | €45.98M |
| Total Shareholders Equity | €-106.65M | €-65.70M |
| Retained Earnings | €-184.21M | €-68.13M |
| Property, Plant & Equipment | €10.72M | €2.49M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IVA | NANO |
|---|---|---|
| Operating Cash Flow | €-24.55M | N/A |
| Capital Expenditures | €-63,000 | N/A |
| Free Cash Flow | €-12.13M | N/A |
| Debt Repayment | €-1,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IVA | NANO |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 108,036 | 301,738 |
| Average Daily Volume (90 Day) | 62,815 | 177,091 |
| Shares Outstanding | 95.66M | 47.40M |
| Float Shares | 53.99M | 24.67M |
| % Held by Insiders | 0.08% | 0.15% |
| % Held by Institutions | 0.64% | 0.28% |
Dividend Analysis & Yield Comparison: Inventiva S.A vs Nanobiotix
| Metric | IVA | NANO |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |